Cargando…
A Chemically Defined TLR3 Agonist with Anticancer Activity
Toll-like receptor 3 (TLR3) agonists such as polyinosinic:polycytidylic acid (poly(I:C)) have immunostimulatory effects that can be taken advantage of to induce anticancer immune responses in preclinical models. In addition, poly(I:C) has been introduced into clinical trials to demonstrate its effic...
Autores principales: | Le Naour, Julie, Thierry, Sylvain, Scuderi, Sarah Adriana, Boucard-Jourdin, Mathilde, Liu, Peng, Bonnin, Marc, Pan, Yuhong, Perret, Clémence, Zhao, Liwei, Mao, Misha, Renoux, Chloé, Pérez-Lanzón, María, Martin, Baptiste, Kepp, Oliver, Kroemer, Guido, Werlé, Bettina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305499/ https://www.ncbi.nlm.nih.gov/pubmed/37389102 http://dx.doi.org/10.1080/2162402X.2023.2227510 |
Ejemplares similares
-
TL-532, a novel specific Toll-like receptor 3 agonist rationally designed for targeting cancers: discovery process and biological characterization
por: Thierry, Sylvain, et al.
Publicado: (2023) -
Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
por: Frega, Giorgio, et al.
Publicado: (2020) -
Trial watch: TLR3 agonists in cancer therapy
por: Le Naour, Julie, et al.
Publicado: (2020) -
Secreted calreticulin mutants subvert anticancer immunosurveillance
por: Liu, Peng, et al.
Publicado: (2019) -
Trial watch: STING agonists in cancer therapy
por: Le Naour, Julie, et al.
Publicado: (2020)